Atara Biotherapeutics Inc
XNAS:ATRA
| Market Cap (Intraday) | 123.37M |
| Current PE | 5.27 |
| Forward PE | 6.09 |
| 2yr Forward PE | 42.93 |
| 10-Day MA | $16.78 |
| 50-Day MA | $14.57 |
| 200-Day MA | $10.64 |
Atara Biotherapeutics Inc Stock, XNAS:ATRA
1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, California 91320
United States of America
Phone: +1.805.623.4211
Number of Employees: 153
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.